Aprinoia Therapeutics (Aprinoia Therapeutics) Total Liabilities : $96.41 Mil (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Total Liabilities?

Aprinoia Therapeutics's Total Liabilities for the quarter that ended in Jun. 2023 was $96.41 Mil.

Aprinoia Therapeutics's quarterly Total Liabilities increased from Jun. 2022 ($0.00 Mil) to Dec. 2022 ($81.09 Mil) and increased from Dec. 2022 ($81.09 Mil) to Jun. 2023 ($96.41 Mil).

Aprinoia Therapeutics's annual Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2021 ($61.45 Mil) and increased from Dec. 2021 ($61.45 Mil) to Dec. 2022 ($81.09 Mil).

Aprinoia Therapeutics Total Liabilities Historical Data

The historical data trend for Aprinoia Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Total Liabilities Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Total Liabilities

61.45

81.09

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Total Liabilities	61.45	-	81.09	96.41

Aprinoia Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aprinoia Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	15.175	+	(0.042	+	65.876
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	81.09

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	5.643	-	-75.45
	=	81.09

Aprinoia Therapeutics's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	30.517	+	(0.015	+	65.876
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	96.41

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	14.476	-	-81.932
	=	96.41

Aprinoia Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines